Definium Therapeutics (DFTX) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
13 Nov, 2026DT120 clinical results
Panorama met all primary and key secondary endpoints; 100 μg improved HAM-A vs. placebo by 5.1 points at week 12 (p<0.0001).
Voyage improved HAM-A vs. placebo by 5.4 points at week 12 and 7.7 points at week 1 (both p<0.0001).
Emerge improved MADRS vs. placebo by 8.1 points at week 6 and 7.3 points at week 12 (both p<0.0001).
Across pivotal readouts, DT120 100 μg was generally well tolerated, with no suicidality signal reported; mean time to EOSC clearance was 5.8–6.4 hours across studies.
Interim extension data through week 28 showed further HAM-A or MADRS improvement with additional open-label treatments in Panorama, Voyage and Emerge.
Development and regulatory plans
Ascend, a Phase 3 MDD study with target n=165, has a 2027 topline readout; Haven, a Phase 3 PTSD study with target n=200, is planned to initiate in 2027.
A pre-NDA meeting for DT120 is anticipated in 4Q 2026, with NDA filing targeted for 1H 2027; regulatory filing strategy for GAD and MDD is to be discussed at the meeting.
DT120 has FDA Breakthrough Therapy Designation in GAD and MDD; the presentation cites a statistically significant Phase 2b dose response and alignment with FDA guidance.
Commercial opportunity
The U.S. market framework identifies 50M adults with GAD or MDD, including 26M diagnosed, 13M prescription-treated and 4.2M failing 2+ prescriptions.
Market research found 58% of surveyed HCPs had positive views of DT120; awareness rose from 27% to 64% from 2024 to 2026, and 51% of high-priority HCPs said they would prescribe and administer it.
A modeled opportunity of $5B gross revenue assumes 2 patients per clinic per month across ~4,000 interventional psychiatry clinics and midpoint surrogate pricing based on Spravato; DT120 pricing is not established.
The proposed commercial model connects patients, providers and care sites through education, access, reimbursement, referral, site-readiness and treatment-day support.
Latest events from Definium Therapeutics
- DT120 targets a one-to-three-dose model, with an H1 2027 NDA plan and a 2027 MDD readout.DFTX
Jefferies Global Healthcare Conference - DT120 targets an H1 2027 NDA; early DT402 findings support continued ASD development.DFTX
Stifel 2026 Healthcare Conference 2026 - Phase 3 DT120 results support an H1 2027 NDA target, with $1.05B projected to fund operations into 2030.DFTX
Q3 2026 - DT120 demonstrated strong efficacy and safety in GAD and MDD, with durable benefits and flexible dosing.DFTX
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - DT120 ODT demonstrated best-in-class efficacy and safety in GAD and MDD, with NDA filing planned for 2027.DFTX
Corporate presentation - DT120 ODT 100 µg achieved rapid, durable efficacy and favorable safety in Phase 3 GAD study.DFTX
Study result - DT120 ODT delivers best-in-class efficacy and safety in GAD and MDD, supporting blockbuster potential.DFTX
Corporate presentation - DT120 ODT showed rapid, robust, and durable efficacy in GAD with strong safety and long-term benefits.DFTX
Study result - Record Phase 3 MDD efficacy, $1.1B cash, and GAD data drive continued pipeline momentum.DFTX
Q2 2026